医学
髓系白血病
疾病
重症监护医学
IDH2型
分子诊断学
IDH1
生物信息学
内科学
突变
生物
生物化学
化学
基因
作者
Hartmut Döhner,Andrew H. Wei,Frederick R. Appelbaum,Charles Craddock,Courtney D. DiNardo,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Lucy A. Godley,Robert P. Hasserjian,Richard A. Larson,Ross L. Levine,Yasushi Miyazaki,Dietger Niederwieser,Gert J. Ossenkoppele,Christoph Röllig,Jorge Sierra,Eytan M. Stein,Martin S. Tallman,Hwei‐Fang Tien,Jianxiang Wang,Agnieszka Wierzbowska,Bob Löwenberg
出处
期刊:Blood
[American Society of Hematology]
日期:2022-07-07
卷期号:140 (12): 1345-1377
被引量:1275
标识
DOI:10.1182/blood.2022016867
摘要
Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
科研通智能强力驱动
Strongly Powered by AbleSci AI